U.S. Markets closed

Dicerna Pharmaceuticals, Inc. (DRNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.67+0.38 (+2.08%)
At close: 4:00PM EDT

Dicerna Pharmaceuticals, Inc.

33 Hayden Avenue
Lexington, MA 02421
United States
617 621 8097
http://www.dicerna.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees187

Key Executives

NameTitlePayExercisedYear Born
Dr. Douglas M. Fambrough IIICo-Founder, CEO, Pres & Director937.43k1.8M1969
Dr. Bob D. BrownExec. VP of R&D and Chief Scientific Officer671.96k564.75k1965
Dr. Ralf H. RosskampConsultant707.13k395.56k1953
Mr. Robert D. Ciappenelli M.B.A.Chief Commercial Officer339.51kN/A1967
Dr. Mark BehlkeCo-Founder & Member of Scientific Advisory BoardN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiometabolic diseases. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise DCR-A1AT programs; and a program for the treatment of neurodegeneration and pain. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, Roche, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.

Corporate Governance

Dicerna Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 9, 2019 is 3. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.